جست‌وجوی استاد و پژوهشگر

Alexis Battleمشاهده پروفایل

دانشیار

• Genomics
• Machine Learning
• Computational Biology
• +۳ مورد دیگر

Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .

Marek Sanakمشاهده پروفایل

استاد

• Genetics
• Asthma
• Lipid mediators of inflammation
• +۷ مورد دیگر

Professor Marek Sanak serves as Full Professor at the Department of Internal Medicine, Jagiellonian University Medical College in Cracow, Poland. He concurrently holds leadership positions as Acting Director of the Department of Forensic Medicine, Head of the Division of Molecular Biology and Clinical Genetics, and Vice-Rector for Research and International Cooperation since 2016. His academic foundation includes: MD from Jagiellonian University Medical College Specialization in Pediatrics and Genetics PhD from Jagiellonian University Research appointments at Harvard University, University of Paris VI, and University of Zurich Professor Sanak's research integrates clinical genetics with molecular immunology, focusing on asthma pathogenesis, lipid mediators of inflammation, and genetic diagnostics. His laboratory employs advanced techniques including deep DNA/RNA sequencing to identify biomarkers and elucidate disease mechanisms. The work bridges fundamental molecular discoveries with clinical applications in respiratory diseases, allergic disorders, and forensic medicine, demonstrating particular expertise in aspirin-exacerbated respiratory disease and epigenetic regulation of inflammatory pathways. Analysis of his recent publications reveals a strategic evolution from classical asthma research toward molecular genetics and viral pathogenesis. His 2017-2021 work increasingly incorporates epigenetic approaches (DNA methylation, microRNA profiling) while expanding into SARS-CoV-2 research during the pandemic. The publications demonstrate interdisciplinary integration across immunology, respiratory medicine, and molecular diagnostics, with consistent focus on translational applications. His distinguished career has been recognized through numerous honors: The Lancet Investigators Award on Asthma (1997) Polish Ministry of Health Individual Prize (1999) Jagiellonian Laurel (2012) Pro Arte Docendi Award (2014/15) Gold Medal for Long Service (2019) Top 2% of world scientists ranking (Elsevier 2022) As Vice-Rector for Research, Professor Sanak has significantly expanded international collaborations with King's College London, University of Southampton, and University of Zurich. His leadership has secured substantial funding for molecular diagnostics and inflammatory disease research while mentoring numerous early-career researchers. He delivers invited lectures globally for organizations including the American Thoracic Society and European Academy of Allergy and Clinical Immunology. Professor Sanak directs integrated research units across the Division of Molecular Biology and Clinical Genetics, Division of Biochemical and Molecular Diagnostics at University Hospital Cracow, and the Department of Forensic Medicine. These teams combine clinical service with basic research to advance genetic diagnostics and understand disease mechanisms, maintaining forensic genetics expertise developed over 20 years of practice.

Paula Gonzalez-Figueroaمشاهده پروفایل

پژوهشگر ارشد

• Immunology
• Autoimmunity
• Allergy
• +۶ مورد دیگر

Dr. Paula Gonzalez-Figueroa is a Research Fellow at the Clinical Hub for Interventional Research (CHOIR) in the College of Health and Medicine at The Australian National University (ANU). She holds a PhD in Medical Sciences from ANU and completed postdoctoral research at the John Curtin School of Medical Research (ANU) and the Francis Crick Institute (UK). Her research focuses on immunology, autoimmunity, allergy, and clinical translation. Education: PhD in Medical Sciences (ANU), Biotechnology degree. Research Interests: Regulatory T cells, germinal centers, B cell biology, neuritin-based therapies, preclinical drug testing, and early-phase clinical trials. Affiliations: CHOIR (Researcher), Polizzotto Group, Genome Sciences and Cancer Division. Her work includes developing a neuritin-based biotherapeutic for allergies and autoimmune diseases, and leading preclinical/Phase I clinical programs for hematological cancers. She has contributed to studies on Tfr cell regulation, IgE responses, and germinal center dynamics. Publications span immunology, molecular biology, and translational research, with notable contributions to Nature Immunology , Cell , and Journal of Experimental Medicine .

• Immunodeficiency Diseases
• Actin Regulators in Immune Cells
• Autoimmunity
• +۳ مورد دیگر

Lisa Westerberg is a Professor of Experimental Immunology at the Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet. Her research focuses on understanding how compromised immune systems lead to immunodeficiency, autoimmunity, and hematological cancers, particularly studying the role of actin regulators in immune cell function. She leads the 'Immunodeficiency Diseases – Lisa Westerberg Group' and collaborates internationally with institutions like Harvard Medical School and the University College London. Education: PhD in Cell and Molecular Biology from Karolinska Institutet (2003), postdoc at Harvard Medical School (2009). Affiliations: Department of Microbiology, Tumor and Cell Biology; WASPSTINGS network (STINT-funded); Swedish Society for Immunology (Treasurer). Research Interests: Immunodeficiency diseases, actin cytoskeleton dynamics in immune cells, cancer immunology, and space immunology. Her lab investigates how genetic mutations in actin regulators affect immune cell communication, migration, and genomic stability. Recent projects include studying immune system adaptation in microgravity and developing therapies targeting actin regulators in cancer. Articles Trends: Recent work highlights immune cell adaptations in space environments, therapeutic modulation of actin pathways, and clonal evolution in lymphomas. Over 15 articles since 2020 explore mechanisms linking immune dysfunction to cancer and immunodeficiency. Awards: Ragnar Söderberg Fellowship, ERC Starting Grant (2019), Wallenberg Academy Fellow. Funding: Swedish Research Council, Knut och Alice Wallenberg Foundation, EU grants. Advising & Grants: Supervised over 40 students (PhD, Master’s, undergrad) since 2010. Active in training programs like the Amgen Scholars initiative. Collaborates with global teams on projects funded by VR, NIH, and international partnerships. Labs/Teams: Leads the core Immunodeficiency Diseases Group and collaborates with the Dosenovic Lab (focusing on B cell vaccine development). The group uses CRISPR, high-resolution microscopy, and single-cell sequencing to study immune mechanisms.

• Microbiomics
• Genomics
• Complex Diseases
• +۴ مورد دیگر

Elin Org is a Professor of Microbiomics at the University of Tartu's Institute of Genomics, where she also serves as Head of the Estonian Genome Centre and Vice Director of the Institute. Her academic career spans over two decades with significant contributions to microbiome and genomic research. Education: PhD in Genetics, University of Tartu (2006) Master's Degree in Molecular Biotechnology and Biomedicine, University of Tartu (2000) Bachelor's Degree, University of Tartu (1997) Classical Singing, Heino Eller Tartu Music School (1996) Professor Org's research primarily focuses on the intricate relationships between host and gut microbiota and their influence on metabolism and common complex diseases. Her work bridges microbiomics, genomics, and complex disease research, with particular emphasis on understanding how gut microbiome composition affects human health. She has pioneered research connecting long-term antibiotic usage with microbiota-dependent effects and has made significant contributions to understanding the role of gut microbiome in conditions such as gestational diabetes, endometriosis, and polycystic ovary syndrome. Her approach integrates advanced computational methods with comprehensive health data to uncover causal relationships in microbiome research. Her recent publications demonstrate a strong trend toward integrating microbiome data with extensive digital health metrics, using machine learning approaches to identify microbial predictors of health outcomes. This work is increasingly focused on translating microbiome research into clinical applications for disease prediction and personalized medicine approaches, particularly in the context of the Estonian Biobank initiative. Major Scientific Recognition: 2025 National Science Award in medical and health sciences 2023 and 2022: Recognized among the world's top 1% most cited researchers by Clarivate Analytics 2020: Member of AcademiaNet, a portal for top female researchers 2017: EMBO Installation grant 2013: Marie Curie International Outgoing Fellowship Professor Org has secured substantial research funding as principal investigator for multiple significant projects, including 'DISCERN - Discovering the causes of three poorly understood cancers in Europe' (€245,466, European Commission) and 'Improving colorectal cancer screening and prediction using microbiome-based biomarkers' (€760,450, Estonian Research Council). She has served as an opponent for numerous PhD theses across European institutions, contributing to the development of emerging researchers in her field. As Head of the Estonian Genome Centre, Professor Org leads a multidisciplinary research team that plays a crucial role in Estonia's transition from biobanking to personalized medicine applications. She is actively involved in international collaborations through COST networks including INFOGUT (focused on in vitro colon models) and ML4Microbiome (statistical and machine learning techniques in human microbiome studies), positioning her at the forefront of global microbiome research initiatives.

Ilse Dewachterمشاهده پروفایل

استاد

• Alzheimer's Disease
• Neurodegenerative Diseases
• Therapeutic Development
• +۶ مورد دیگر

Prof. Ilse Dewachter is the head of the Biomed Neuroscience research group at Hasselt University (UHasselt), specializing in Alzheimer’s therapy and prevention for over 25 years. Her work focuses on multi-targeted therapies targeting tau, inflammation, and ApoE, alongside pioneering research into disease prevention via blood-based biomarkers. Recent studies explore a protective APOE3ch mutation that halted Alzheimer’s progression in a patient, offering hope for new treatments. Research Interests: - Alzheimer’s disease mechanisms (Abeta, tau, inflammation) - Multi-target therapies and biomarker development - Neurodegenerative disease prevention strategies - Genetic mutations impacting disease progression Articles Overview: Her most recent work (2025-2022) addresses neuroinflammation, tau propagation models, and AI-driven neuroimaging. Key themes include APOE genetics, blood-brain barrier dynamics, and exercise impacts on cognition. Funding & Grants: Current projects require significant investment for advanced biomarker equipment and clinical trials. A notable €300,000 grant funded research on brain lipid metabolism’s role in Alzheimer’s. Labs & Teams: Leads the BIOMED Neuroscience group at UHasselt, collaborating internationally on preclinical models and drug development.

• Drug Delivery
• Pharmaceutics
• Nanomedicine
• +۵ مورد دیگر

Caitriona M. O'Driscoll is Professor and Chair of Pharmaceutics at University College Cork's School of Pharmacy, Ireland. With over four decades of academic experience, she previously served as Head of the School of Pharmacy at UCC from 2003-2009 and 2010-2013. Her established drug delivery research team spans from pre-formulation through to production and manufacture of prototype delivery systems suitable for clinical trial, with strong industry links underpinning many research projects. Her research interests focus on translational drug delivery with emphasis on 'problem' drugs including poorly water soluble compounds and biopharmaceuticals like peptide/protein drugs, plasma DNA and siRNA. She develops nano-sized delivery constructs that are robust enough to survive processing, stable on storage, and achieve cell/site specific delivery in vivo. Greater than 40% of new chemical entities are poorly water soluble Biopharmaceuticals now approach 50% of all new drugs in development Major barrier is design of efficient delivery systems Special focus on oral drug delivery despite challenges Analysis of her recent publications reveals a strong emphasis on targeted nanodelivery systems for cancer therapy, particularly prostate and colorectal cancer, as well as neurodegenerative diseases like Huntington's. Her work demonstrates expertise in cyclodextrin-based nanoparticles, siRNA delivery, and disease-specific formulations that account for conditions like Crohn's disease that affect drug delivery. Scientific awards include: 'Person of the Year award' by Parenteral Drug Association (Ireland Chapter) in 2013 'Award for Professional Excellence' by Helix Health in 2007/2008 'Award for Pharmacist of the Year' by Helix Health in 2007/2008 With €10.5M in career research income and 25 PhDs graduated, Professor O'Driscoll's work has attracted funding from diverse sources including Science Foundation Ireland, Enterprise Ireland, and industry partners. Her research group maintains strong links with Pharmaceutical Chemistry and Process & Chemical Engineering at UCC, creating a unique strength for drug development research from design through to clinical trial. She has served as external examiner for multiple universities and as PhD thesis examiner at institutions worldwide. Her research team operates within UCC's drug delivery group, which has established expertise spanning from pre-formulation through to production and manufacture of prototype delivery systems. The group maintains strong industry connections and offers various PhD positions, focusing particularly on translational research with product-driven applications.

Tyler Johnsonمشاهده پروفایل

دانشیار

• Natural Products Chemistry
• Bioorganic Chemistry
• Medicinal Chemistry
• +۲ مورد دیگر

Tyler Johnson, PhD, is an Associate Professor in the Department of Natural Sciences and Mathematics at Dominican University of California's School of Health and Natural Sciences. His expertise lies in Natural Products Chemistry , Bioorganic Chemistry , and Medicinal Chemistry , with a focus on biomedical applications. Johnson's research emphasizes discovering therapeutic lead compounds and molecular probes from marine and terrestrial natural products. His research team investigates chemotypes like mycothiazole , zampanolide , fijianolide , and latrunculin from Indo-Pacific marine sponges. These compounds exhibit potent cytotoxicity (IC50 1~5 nM) against cancer cell lines through mechanisms including microfilament disruption , mitochondrial complex I inhibition , and microtubule stabilization . Current work explores mycothiazole as a molecular probe for mitochondrial aging. Key publications span 2024-2002, covering topics from sponge-derived anticancer agents to inflammation modulation and environmental toxicology. Johnson's laboratory engages in large-scale natural product isolation, spectroscopic validation, and semi-synthetic medicinal chemistry to optimize therapeutic leads. His work integrates undergraduate and graduate students into interdisciplinary biomedical research.

Joanne Wangمشاهده پروفایل

استاد

• Blood-brain and blood-csf barriers
• Pharmacokinetics-Pharmacodynamics
• Pharmacology
• +۵ مورد دیگر

Joanne Wang is Professor of Pharmaceutics at the University of Washington School of Pharmacy and an Affiliate Investigator at the Fred Hutchinson Cancer Research Center. She holds additional appointments in multiple research centers including the Obstetric-fetal Pharmacology Research Unit (OPRU), Plein Center for Aging Faculty, and Pharmaceutics Faculty. Her educational background includes: PhD in Pharmaceutical Chemistry, University of California, San Francisco (UCSF) MS in Biochemistry, University of Illinois at Chicago BS in Biochemistry, Peking University Dr. Wang's research focuses on solute carrier (SLC) and ATP-binding cassette (ABC) transporters that shuttle drugs, nutrients, neurotransmitters, and hormones across cell membranes. Her work encompasses elucidating mechanisms and clinical impact of transporters in nutrient and drug disposition and their potential as drug targets. Ongoing projects include identification and functional characterization of transporters in human placenta, mechanisms of drug secretion into breastmilk using PBPK modeling, and investigation of transporters in the disposition of meta-iodobenzylguanidine for cancer therapy. Analysis of her recent publications reveals a strong emphasis on transporter-mediated drug disposition in special populations, particularly during pregnancy and lactation, and at the blood-brain barrier. Her work spans from basic transporter characterization to clinical applications, with increasing focus on translational aspects including PBPK modeling and clinical implications of transporter polymorphisms. Dr. Wang is actively involved in mentoring, as evidenced by her lab accepting students. Her research has been supported by significant grants including a UC2 grant from NICHD for placental transporter research. Her multidisciplinary approach integrates in vitro models, in vitro-in vivo extrapolation, and PBPK modeling to address critical questions in drug disposition. She is affiliated with several research centers including the Obstetric-fetal Pharmacology Research Unit (OPRU), Plein Center for Aging, and the Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH), reflecting the breadth and impact of her work across multiple domains of pharmacology and therapeutics.

Judy Hartمشاهده پروفایل

دانشیار

• Renewable Energy Materials
• Photocatalysis
• Solar Cells
• +۵ مورد دیگر

Associate Professor Judy Hart is a materials scientist at the School of Materials Science & Engineering, UNSW Sydney , specializing in the development of semiconducting materials for renewable energy applications. Her work integrates computational (DFT) and experimental approaches to understand composition-property relationships in systems like solid solutions , heterostructures , and doped materials for photocatalysis and solar cells . She leads projects funded by ARC Discovery and Linkage grants , including work on photo-electro-catalysis systems and stabilizing ceramic materials . Education: PhD in Materials Engineering (Monash University, 2007), BEng (Materials) (Monash, 2002) Professional Experience: Senior Lecturer (UNSW, 2017–), Lecturer (UNSW, 2013–2017), University of Bristol (2007–2012) Research Interests Her research focuses on designing materials for renewable energy , particularly photoelectrochemical water splitting and organic oxidation reactions . Key areas include Density Functional Theory (DFT) , defect engineering , band gap tuning , and nanostructured materials . She investigates ferroelectric polarization effects , metal oxide heterostructures , and stability of battery components , with applications in hydrogen production , CO2 conversion , and advanced battery materials . Scientific Awards Ramsay Memorial Fellowship (University of Bristol, 2007–2009) Teaching Contributions She is co-author of the 1st Australian & New Zealand edition of "Materials Science and Engineering: An Introduction" , and teaches courses on computational materials science , corrosion-resistant surfaces , mechanical behavior of metals , and materials design .

Marshall J. Glesbyمشاهده پروفایل

استاد

• HIV Pathogenesis
• Aging in HIV Patients
• Co-infections
• +۵ مورد دیگر

Marshall J. Glesby is a Professor at Weill Cornell Medical College, affiliated with both the Department of Medicine and Population Health Sciences. His career spans over three decades, focusing on HIV pathogenesis, aging-related complications, and co-infections. He holds a Ph.D. from Johns Hopkins University School of Hygiene and Public Health (1997), an M.D. from Johns Hopkins University School of Medicine (1989), and a B.Sc. from McGill University (1985). Research Interests: His work integrates HIV, immunology, and public health, emphasizing co-infections, metabolic disorders, and cardiovascular complications. Recent studies explore geriatric syndromes, epigenetic aging, and biomarkers like extracellular vesicles in Long COVID and Alzheimer's disease. He leads clinical trials on Mpox severity scoring and HIV-kidney transplantation. Grants and Collaborations: Dr. Glesby is a key investigator for NIH-funded projects, including PORTENT (NIAID) and STRIVE (NIAID). He contributes to global HIV research networks like INSIGHT and ACTG, with subawards from the National Institute of Child Health & Human Development and NHLBI. External Relationships: He serves as a consultant for UpToDate, Inc., and collaborates with organizations such as the Northeast/Caribbean AIDS Education and Training Centers.

• Gastrointestinal Pathology
• Inflammatory Bowel Disease
• Colorectal Carcinoma
• +۷ مورد دیگر

Lindsay Alpert is an Associate Professor in the Department of Pathology at the University of Chicago's Pritzker School of Medicine. As a surgical pathologist specializing in gastrointestinal pathology, Dr. Alpert provides expert diagnostic services for neoplastic and non-neoplastic diseases of the gastrointestinal tract, biliary tree, and pancreas. Dr. Alpert received her MD from Columbia University College of Physicians and Surgeons in 2012. She completed her residency in Anatomic Pathology and fellowship in Gastrointestinal and Hepatic Pathology at the University of Chicago, finishing her fellowship in 2016 and residency in 2017. Dr. Alpert's research focuses on gastrointestinal pathology with particular expertise in inflammatory bowel disease, colorectal carcinoma, and the gut microbiome. Her work examines dysplasia patterns in IBD patients, histologic features of enteropathies, and the impact of therapeutic interventions on gastrointestinal tissues. She has made significant contributions to understanding the histologic spectrum of various gastrointestinal conditions and their clinical implications, with numerous publications in high-impact journals like Modern Pathology and Gastroenterology. Analysis of Dr. Alpert's recent publications reveals a strong focus on gastrointestinal pathology, particularly inflammatory bowel disease and colorectal neoplasia. Her work spans diagnostic pathology, molecular characterization of gastrointestinal tumors, and the impact of therapeutic interventions. Many studies examine dysplasia patterns in IBD patients across different age groups and presentations, while others investigate rare gastrointestinal conditions and their histologic features. Her research often bridges basic science with clinical applications, examining how dietary and pharmacological factors influence gastrointestinal pathology. Dr. Alpert actively collaborates with numerous researchers and clinicians at the University of Chicago and beyond, contributing to multidisciplinary studies that bridge pathology with clinical gastroenterology and oncology. Her network includes prominent colleagues such as John Hart, Namrata Setia, and Shu-Yuan Xiao. Dr. Alpert maintains an active research laboratory focused on gastrointestinal pathology, where she mentors trainees and collaborates with colleagues on various research projects examining the histopathology of gastrointestinal diseases. Her team works closely with clinicians to translate pathological findings into improved diagnostic criteria and patient care, particularly for complex cases involving inflammatory bowel disease and gastrointestinal neoplasia.

• DNA Nanotechnology
• Molecular Robotics
• Self-Assembling Nanostructures
• +۴ مورد دیگر

Dr. Shelley Wickham is an Associate Professor and ARC DECRA Fellow at the University of Sydney, holding joint appointments in the Schools of Chemistry and Physics. She serves as a Westpac Research Fellow and leads the DNA Nanotechnology Group at the Sydney Nano Institute. Dr. Wickham is also co-Champion of the Sydney Nano Institute Grand Challenge project in Molecular Nanorobotics for Health, co-lead of the School of Physics Grand Challenge on Nanoscale brain navigation for targeted drug delivery, and faculty mentor of the University of Sydney BIOMOD team. Bachelor of Science and Master of Science in Physics from University of Sydney PhD in Condensed Matter Physics from University of Oxford Postdoctoral Fellow at Harvard Medical School, Dana-Farber Cancer Institute, and Wyss Institute Dr. Wickham's research focuses on self-assembling nanotechnology and molecular robotics, particularly in the design and assembly of programmable nanostructures out of DNA. Her work spans applications in cell biology, materials science, and nanomedicine. Current research projects include design and synthesis of self-assembling DNA nanostructures, proto-cells made of DNA gels that move under flow, new plasma fabrication methods for biomolecule micropatterning, and DNA computation circuits for navigating the brain using machine learning. Her research aligns with the Faculty of Science Research Strengths in Molecules to Materials, Preventing and Treating Disease & Disorder, and Next Generation Materials. Analysis of Dr. Wickham's recent publications reveals a consistent focus on DNA nanotechnology with increasing sophistication in structural complexity and biological applications. Her work has evolved from fundamental DNA origami structures to increasingly complex multi-component systems with practical applications in nanomedicine and biomimetic engineering. Recent publications show strong interdisciplinary collaboration across chemistry, physics, biology, and engineering disciplines, with emphasis on real-world applications including drug delivery systems and biomolecular sensors. ARC DECRA Fellow Westpac Research Fellow BIOMOD World Champions (2019) Dr. Wickham actively mentors PhD students and postdoctoral researchers in her DNA nanotechnology group. She has secured significant research funding including ARC Discovery Projects, Westpac Scholarships, and NSW Health grants. Her current grants support projects such as '3D Bio-Nanomaterial Displays with Designer Architectures and Functions' and 'RNA aptamer sensing devices for rapid detection of blood clotting.' Dr. Wickham encourages applications from diverse backgrounds and maintains active collaborations with researchers at Harvard, Oxford, and other international institutions. Dr. Wickham leads the DNA Nanotechnology Group at the University of Sydney, which is part of the Sydney Nano Institute. Her lab focuses on building tools from DNA origami - including tweezers, spanners, wrenches and springs - to better understand biological processes at the nanoscale. The group has achieved notable success with the BIOMOD team winning world championships in 2019, and continues to develop innovative approaches to molecular robotics for healthcare applications.

• Genetics
• Biometry
• Public Health
• +۷ مورد دیگر

Samuli Ripatti is a Professor of Biometry at the Faculty of Medicine, University of Helsinki, and Director of the Institute for Molecular Medicine Finland (FIMM). He chairs the Research Council Finland’s Centre of Excellence in Complex Disease Genetics and the EU H2020-funded Intervene Consortium. His research focuses on genetic variation in the Finnish population, particularly its effects on cardiometabolic diseases and cancers, with a strong emphasis on polygenic risk scores for disease prevention and early detection. His work spans Genetic risk prediction models Lipidomic and metabolomic profiling Gene-environment interactions Translational genomics Recent research highlights include 1099 plasma metabolite-disease causal analysis Genetic determinants of weight loss interventions Cardiovascular risk stratification tools Leukocyte lipid metabolism pathways He actively supervises doctoral programs in Integrative Life Science, Social Sciences, Clinical Research, and Population Health, and collaborates with the Broad Institute of MIT and Harvard.

Doron Betelمشاهده پروفایل

استادیار

• Computational Genomics
• Bioinformatics
• Single-cell RNA-seq Analysis
• +۳ مورد دیگر

Doron Betel serves as an Assistant Professor at Weill Cornell Medicine's Graduate School of Medical Sciences, with affiliations in both the Physiology, Biophysics & Systems Biology and Computational Biology programs. He directs the Applied Bioinformatics Core (ABC), a central service group providing specialized computational and analytical support for biomedical research across multiple institutions. Dr. Betel's research focuses on developing computational genomic tools for studying human diseases and cellular development, with emphasis on integrative analyses of genomic and epigenomic data from high-throughput assays. His work addresses specific questions related to disease progression, treatment response, stem cell differentiation, and neurological processes through two closely interacting research groups: the Applied Bioinformatics Core and his independent research lab. The analysis of his recent publications reveals a strong emphasis on single-cell and spatial genomics, cross-species data integration, and machine learning applications in cancer immunology and neurodegenerative disease modeling. His research spans multiple high-impact areas including cancer immunotherapy, stem cell biology, diabetes research, and cardiovascular regeneration, with numerous publications in top journals like Nature, Cell, and Nature Immunology. Through the Applied Bioinformatics Core, Dr. Betel provides extensive analytical support across various genomic platforms including single-cell RNA-seq, spatial transcriptomics, ChIP-seq, ATAC-seq, and variant calling. The Core serves as a vital resource for researchers at Weill Cornell Medicine and the broader Tri-Institutional network, offering specialized analysis, computational pipelines, and training services. Dr. Betel maintains extensive collaborations with leading researchers including Lorenz Studer at MSKCC for stem cell and neurodegenerative disease research, Tuomas Tammela for cancer genomics, and multiple immunology researchers studying T cell function in autoimmunity and cancer. His work bridges computational methodology development with direct biomedical applications across multiple disease areas.